An interventional study of laser indirect ophthalmoscopy pan retinal photocoagulation in Proliferative Diabetic Retinopathy - High Risk, sponsored by Wills Eye. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-12-16.
Sponsored by Wills Eye · Not applicable, Interventional, and Treatment
Our aim is to compare patient comfort when using the 532 nanometer (green) wavelength laser to the 577 nanometer (yellow) wavelength laser during pan retinal photocoagulation to treat patients with diabetic retinopathy. Secondary outcome measures will be power (mW) required to achieve gray-white retinal burns and duration of treatment.
As demonstrated in the Diabetic Retinopathy Study (DRS), panretinal photocoagulation (PRP) reduces the risk of severe vision loss in patients with proliferative diabetic retinopathy. The DRS recommended that PRP treatment consist of 1,200 - 1,600 laser burns 500 µm in size, one half to one burn width apart, applied to the peripheral retina in a scatter fashion. Most patients who undergo PRP experience discomfort/pain during the procedure. Once present, pain can affect the number and quality of burns delivered and can indirectly increase the number of sessions required to complete the therapy.This may in turn adversely affect patient compliance. Although retrobulbar and peribulbar blocks can provide adequate anesthesia for PRP, these anesthetic methods carry rare but serious risks such as retrobulbar hemorrhage. Previous studies have explored other ways to reduce discomfort related to PRP, including optimization of laser settings, oral and topical analgesics, subconjunctival anesthesia, and even acupuncture.
Currently, green lasers (521 - 532 nm wavelength) are most commonly utilized for performing PRP in clinical practice. Yellow lasers (577 nm wavelength) have been of recent interest in treating diabetic macular edema with micropulse subthreshold grid photocoagulation, but have not been extensively studied in PRP for diabetic retinopathy. Compared to shorter wavelength laser, yellow laser comports high transmission through dense ocular media and less light scattering than shorter wavelengths which minimizes spot size and reduces thermal spread. The limited literature comparing green and yellow laser for PRP in diabetic retinopathy has shown that yellow laser requires less power to achieve a retinal burn. In theory this should translate into a reduction in perceived pain experienced during PRP, however a comparison of green and yellow lasers in this regard has not yet been directly examined and quantified.
815 studies on the registry are indexed under Retinal Diseases; 105 are open to participants now.
This study's enrollment of 40 is below the median of 60 across 500 interventional studies indexed under Retinal Diseases.
Browse Retinal Diseases studies →Wills Eye is the lead sponsor of 74 studies on the registry; 3 are open to participants now.
Of its 12 completed or terminated interventional studies of FDA-regulated products, 10 (83%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
scatter laser indirect ophthalmoscopy pan retinal photocoagulation
Procedure: laser indirect ophthalmoscopy pan retinal photocoagulation
scatter laser indirect ophthalmoscopy pan retinal photocoagulation
Procedure: laser indirect ophthalmoscopy pan retinal photocoagulation
* Prior to procedure, eligible patient is dilated and a topical anesthesia is administered 3 to 5 minutes prior to treatment initiation * Treatment duration is fixed at 50 minutes and power is titrated until moderate gray-white burns are achieved, avoiding long ciliary nerves * Target treatment of 250 spots * Only one eye per eligible patient randomized with regard to whether green or yellow laser utilized first * After treatment,pain assessment conducted:spot count, laser parameters and treatment duration recorded for each respective laser wavelength
Also known as: PRP laser
Perceived patient pain assessment
Assessed using a standardized Wong-Baker faces pain scale
Time frame: a single time point within 2 minutes of completing laser treatment
Minimum power requirement to achieve moderate gray-white retinal burns
Time frame: During treatment
Time of treatment
Time required to treat with each laser
Time frame: During treatment
Plan to share: Yes — Manuscript is under development.
This study is completed, as verified in Dec 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Wills Eye